I
n the late 1970s, the laboratories of Schlossman and Kunkel (1, 2) demonstrated that circulating human peripheral blood T cells can express MHC class II (MHC-II) 3 determinants and that the frequency of these MHC-II ϩ CD4 T cells increases after T cell activation. The expression of MHC-II on activated T cells occurs in most mammalian species except for mice, as their T cells cannot transcribe CIITA that is required for MHC-II expression (3, 4) . Although MHC clearly plays a pivotal role in the cellular and humoral immune response by its presentation of peptides to T cells, the expression of MHC-II DR on human T cells has been regarded primarily as simply a marker of "activated" T cells. Nevertheless, MHC-II molecules expressed on human T cell clones are functional, as DR ϩ CD4 T cells can present peptide Ags to other T cells (5) (6) (7) (8) . Moreover, the consequence of MHC-restricted Ag presentation by DR ϩ CD4 cells to autologous T cells is a dominant tolerance that persists even in the presence of macrophages and other so-called "professional" APCs. This tolerance is mediated by LFA3 (CD58)-CD2 interactions indicating that T-T contact in humans involves engagement of both the TCR and CD2. Because murine T cells lack both MHC-II and CD58, the potential importance of T cell expression of MHC-II and CD58 cannot be examined in mouse models of tolerance and suggest that there may be differences in mechanisms of tolerance that have evolved between the two species.
CD4 ϩ CD25 ϩ regulatory T cells (Treg) play a fundamental role in immune homeostasis via their ability to down-modulate the activation of T cells. Mouse CD4 ϩ CD25 ϩ T cells have been shown to be central in the control of self responses in a number of mouse models of autoimmunity. Deletion of Treg by thymectomy in 3-day-old mice results in a spontaneous multiorgan autoimmune disease that is prevented by the adoptive transfer of CD4 ϩ CD25 ϩ T cells (9 -13) . Mouse CD4 ϩ CD25 ϩ Treg also inhibit the proliferation of responder T cells (Tresp) in established in vitro coculture assays that provide an in vitro model to assess their in vivo suppressive ability (14) . Similar in vitro experiments using CD4 ϩ CD25 ϩ cells isolated from the circulation or thymus of humans were critical in providing evidence that human CD4 cells expressing high levels of CD25 (15) (16) (17) (18) (19) were functionally similar and corresponded to the Treg identified in the mouse (20, 21) . These studies demonstrated that in vitro CD4 ϩ CD25 ϩ cells from both species suppress IL-2 gene transcription by cocultured Tresp via a mechanism involving cell contact. Additional similarities between human and mouse Treg, such as the expression of CD62L high and the abrogation of anergy and suppression by providing exogenous IL-2, also have been demonstrated (18, 22, 23) . Thus, the similar in vitro characteristics between mouse and human CD4 ϩ CD25 ϩ T cells suggest that the in vitro investigation of Treg isolated from human autoimmune and infectious diseases can reflect the in vivo function of Treg (24) .
We have demonstrated previously that, in humans, highly homogeneous Treg are best purified if only the ϳ2-3% of CD4 cells that express the highest levels of CD25 are isolated (15) . Restricting the isolation to CD25 high cells increases the homogeneity of the Treg population, as indicated by function and by surface expression of CD45RO, CD122, and CD62L high (15, 18) . Furthermore, using newly described mAbs specific for human Foxp3 via intracellular staining, the cells expressing the highest levels of intracellular Foxp3 protein were shown to again be represented by the population of CD4 T cells expressing the highest levels of CD25 (25) . Yet our initial work indicated that the CD4 ϩ CD25 regulatory population is still heterogeneous, because 20 -30% also express DR (15 
Materials and Methods

Cell culture reagents and Abs
Cells were cultured in RPMI 1640 medium supplemented as described previously (17) with 5% human AB serum (SeraCare Life Sciences) in 96-well U-bottom plates (Costar) or Transwell plates (Nunc). The anti-CD3 (UCHT1 for bead and Hit3a for soluble stimulation) and anti-CD28 (28.2) Abs were purchased from BD Pharmingen. The anti-CD2 Ab (BMA 0111) was purchased from Dade Behring. To generate different stimuli, tosyl-activated beads (Dynal Biotech) were covalently bound with anti-CD3 alone, anti-CD3 and anti-CD2, or anti-CD3 and anti-CD28 at 1 g/ 10 7 beads per the manufacturer's instructions and were used at 1.5 ϫ 10 4 beads/well. In certain experiments, anti-IL-10 (JES3-9D7; BD Pharmingen) was added at 5 g/ml. Staining for intracellular cytokines was performed on cells stimulated with anti-CD3/anti-CD2 for 48 h, during which GolgiStop (BD Pharmingen) and PMA and ionomycin were added for the last 12 h before they were fixed and permeabilized (Cytofix/Cytoperm reagents; BD Pharmingen), and stained separately with allophycocyaninlabeled anti-IL-4, anti-IL-10, or anti-IFN-␥ Abs. Nonspecific background levels (control cytokine staining) were determined for each cytokine by incubating the permeabilized cells with each unlabeled cytokine specific mAb for 10Ј before adding the same, but fluorochrome-labeled anticytokine mAb. Staining for intracellular Foxp3 protein was performed on cells directly after ex vivo isolation with the PCH101 anti-Foxp3 Ab (eBioscience) per the manufacturer's instructions.
Cell isolation
Whole mononuclear cells were isolated from human blood drawn (from 16 different healthy control individuals) in green-capped, heparinized tubes by Ficoll-Hypaque (Amersham Biosciences) gradient centrifugation. Total CD4 T cells were isolated via the CD4 ϩ T cell isolation kit II (Miltenyi Biotec). CD4 T cells were stained for four-color sorting with anti-CD4 (clone RPA-T4) (optional), anti-CD25 (clone M-A251), anti-CD62L (clone Dreg 56), and anti-HLA-DR (clone L243). All Abs were purchased from BD Pharmingen and used after they had been dialyzed to remove azide. The specific DR ϩ and DR Ϫ Treg populations were isolated by sorting with a FACS Aria (BD Biosciences) to typically Ͼ98% purity in postsort analysis. The sorted cells were gated first on small lymphocytes by forward and side scatter, then on CD4 (optional, due to their sample being preselected to be ϳ99% CD4 T cells) and CD62L
high expression, and then on CD25 and HLA-DR expression. In samples not directly stained for CD4, a separate control was analyzed with CD4 to demonstrate the typical 95-99% purity for CD4.
In vitro micrococulture assay
In all assays using cell populations isolated directly ex vivo, the CD4 ϩ CD25 Ϫ (Tresp) cells were plated at 2.5 ϫ 10 3 /well, while the DR ϩ or DR Ϫ Treg were plated at 1.25 ϫ 10 3 /well, and cocultures were at a 2:1 ratio. No irradiated accessory cells were added. A total of 1.5 ϫ 10 4 beads coated with anti-CD3 alone, anti-CD3/anti-CD2, or anti-CD3/anti-CD28 was added per well. The day on which the triplicate assays were set up was considered day 0. To determine proliferation on days 3, 4, and/or 5, half of the culture supernatant (100 l) was replaced with 1 Ci of [ 3 H]thymidine (NEN) at 24-h intervals for a 24-h pulse so that the entire final 3 days of the culture would be monitored. All assays exhibited Ͻ10% SEM and were repeated a minimum of three times using blood from different donors. In experiments using CFSE and/or fluorescence analysis of protein expression, the Tresp were labeled with 0.25 M CFSE as described (26) , and fluorescence was assessed on a FACSCalibur (BD Biosciences) using CellQuest Pro software (BD Biosciences).
Generating clones
For the single-cell cloning experiments, CD4
ϩ CD62L high cells that also gave the profiles of DR Ϫ CD25 Ϫ (Tresp), DR ϩ CD25 Ϫ/low , DR ϩ Treg, and DR Ϫ Treg were sorted at one cell per well and stimulated with soluble anti-CD3 (Hit3a, 2.5 g/ml) and anti-CD28 (28.2, 1 g/ml), 1-5 ϫ 10 4 irradiated (3000 rad) PBMC, and 100 U/ml IL-2 (rhIL-2, Tecin; NCI), as modifications to previously published procedures (18, 27) . Half of the medium was replaced with fresh medium containing 100 U/ml IL-2 starting at day 10 and every 3-4 days thereafter. The Treg clones were generated by stimulation with anti-CD3/anti-CD28/IL-2, because it gave a significantly higher cloning frequency than PHA (data not shown). After 21 days, the cells were restimulated once with PHA-P (REMEL) at 0.5 g/ml with a mixture of irradiated PBMC (25% allogeneic, 75% autologous) at 1-5 ϫ 10 4 /well. The clones were again given fresh IL-2 medium every 3-4 days and were analyzed after 21 days. Tresp/well via ␣CD3 stimulation (bead bound) in the absence of accessory cells. Clones were classified as suppressive if they resulted in coculture proliferation that was equivalent or below the proliferation of the Tresp alone (Ͻ2500 cpm), and if decreasing numbers of cloned cells resulted in increasing proliferation. The clones that satisfied both of these criteria were classified as suppressive. These two criteria were applied so that all clones could be tested regardless of their levels of expansion to minimize the effects of errors in counting small numbers of cells. Clone mRNA analysis. RNA also was isolated from those clones that had grown to sufficient levels to be in excess of the number required for the functional suppressive assay, representing 6-10 clones from each T cell subset and including both suppressive and nonsuppressive clones. These RNA samples were interrogated by real time PCR for expression of Foxp3, IL-10, and TGF␤, relative to ␤ 2 -microglobulin (␤ 2 m) and to each other. Although only a low number of clones were selected for RNA analysis, the frequency of suppressive clone RNA samples in each group basically mirrored the frequency of suppressive clones seen in the larger group of clones, even though they had been selected before functional characterization.
Cytokine analyses by cytometric bead array (CBA)
The supernatants that were removed before addition of [ 3 H]thymidine were analyzed without dilution for the presence of IFN-␥, IL-10, and IL-4 via the Human Th1/Th2 Cytokine CBA kit (BD Pharmingen) per the manufacturer's instructions. The beads were analyzed on a FACSCalibur using the CBA software purchased from BD Pharmingen. Upon initial comparison with ELISA analysis of the cytokine levels, the CBA data were very similar, highly reproducible, but much more sensitive.
values are presented as the difference in C t values normalized to ␤ 2 m for each sample as per the following formula: Normalized expression ϭ (power(2,Ϫ⌬Ct)) ϫ 1000. high Treg were isolated from negatively selected CD4 peripheral blood T cells and examined for functional activity in vitro. CD4 cells were first gated on high expression of CD62L (L-selectin), as described previously (18, 22) (Fig. 1A) . The CD62L
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Frequency and Foxp3 expression by DR
Ϫ population, representing in vivo-activated CD4 T cells (13% of total CD4 cells), express intermediate levels of CD25. In contrast, the CD62L high subset, representing ϳ82% of CD4 T cells that have presumably not been activated in vivo (23, 28) , contains the CD4 ϩ CD25 high population that exhibits in vitro regulatory activity (15, 18 (32) .
Distinct regulatory activity of DR ϩ and DR Ϫ Treg populations
We then examined whether the DR ϩ and DR Ϫ Treg populations were both capable of suppressing the proliferation of CD4 ϩ CD25 Ϫ Tresp in the in vitro coculture assay. In these experiments, because the total CD25 high CD62L high T cells that represent only 2.5% of the total CD4 population were further sorted into separate DR ϩ and DR Ϫ populations, the cell separations typically produced ϳ0.8 ϫ 10 5 DR ϩ Treg and ϳ2 ϫ 10 5 DR Ϫ Treg from ϳ2 ϫ 10 8 total PBMC. As a result, these cell populations were tested for regulatory function in a highly defined in vitro coculture microassay system that lacked APCs and included beads coated with ␣CD3 alone (Fig. 2C) , ␣CD3/␣CD28 (Fig. 2B) model interactions with APCs expressing CD80/86, or ␣CD3/ ␣CD2 ( Fig. 2A) to model signals generated through CD2 by interaction with the high levels of CD58 that are expressed on many types of cells, including accessory cells, endothelial cells, and activated T cells (33, 34) . Proliferation and cytokine secretion were measured by [ 3 H]thymidine incorporation and by a highly sensitive cytokine bead array. In response to ␣CD3 stimulation, the 2500 CD4 ϩ CD25 Ϫ Tresp proliferated, while the DR ϩ and DR Ϫ Treg subsets did not (Fig. 2C) . In contrast, cocultures of Tresp stimulated in the presence of half as many DR ϩ or DR Ϫ Treg exhibited no proliferation. Because this ␣CD3 stimulation alone is weak, proliferation could be detected only at day 5 and was accompanied by the secretion of IFN-␥ only. These data demonstrate that both DR ϩ and DR Ϫ Treg subsets can exhibit in vitro suppressive function under conditions of weak strength of signal associated with ␣CD3 cross-linking alone.
To better model human in vivo stimulatory conditions, we examined the effects of costimulation on the anergic and suppressive characteristics of the DR ϩ and DR Ϫ Treg populations. Human T-T cell interactions involve engagement of both TCR by MHC and CD2 by CD58 (6, 33, 34) , while typical T cell-APC interactions involve engagement of the T cell's TCR and CD28. To address these more physiologically relevant conditions, assays were performed assessing the regulatory activity of DR ϩ and DR Ϫ Treg in response to ␣CD2 or ␣CD28 costimulation (Fig. 2, A and B) . In contrast with the day 5 measurement of proliferation in cultures stimulated with ␣CD3 alone, the presence of a costimulatory signal resulted in an earlier Tresp proliferation that started at day 3 and was accompanied by increased cytokine secretion.
The DR ϩ and DR Ϫ Treg exhibited a striking difference in their kinetics of suppression subsequent to the engagement of CD2. Compared with the strong proliferation of Tresp, ␣CD3/␣CD2-stimulation did not induce the proliferation of either the DR ϩ or DR Ϫ Treg subsets ( Fig. 2A) . The cocultures established with the DR ϩ Treg under ␣CD3/␣CD2 stimulation exhibited a robust and early suppression (day 3) as indicated by the strong inhibition of proliferation and secretion of all measured cytokines, including IFN-␥, IL-10, and IL-4. In marked contrast, cocultures of DR Ϫ Treg and Tresp did not induce a similar early contact-dependent suppression, but rather, induced secretion of IL-4 and IL-10. This was followed by a late contact-dependent suppression (day 5) of both proliferation and IFN-␥ secretion but not IL-4 or IL-10 production. Importantly, the late suppression was shown not to be due to culture exhaustion, because control cultures of Tresp alone were still exhibiting increasing proliferation at this point. Furthermore, the difference in kinetics of suppression by the DR ϩ and DR Ϫ Treg subsets was not simply a reflection of a delay in DR expression by DR Ϫ Treg as Ͻ5% of the DR Ϫ Treg expressed DR during the course of these 5-day cultures.
To determine the source of the increase in secreted IL-4 and IL-10 in supernatants from DR Ϫ Treg cocultures, CFSE-labeled Tresp, DR ϩ Treg, DR Ϫ Treg, or the specific Treg/CFSE Tresp cocultures were stimulated with ␣CD3/␣CD2 and exogenous IL-2 and stained for intracellular cytokine production (Fig. 2D ). IL-2 was added to augment cytokine production, although it also abrogated coculture suppression as expected. Also, although the DR ϩ Treg do not typically secrete any detectable cytokines, they were similarly analyzed to allow the comparison between the DR ϩ and DR Ϫ Treg populations. These data demonstrate that, while both the DR Ϫ Treg and Tresp subsets can produce IL-4 and IL-10 under these conditions, a greater proportion of DR Ϫ Treg produced IL-4 (25%) and IL-10, while a greater proportion of the Tresp produced IFN-␥ (18%). Thus, the DR Ϫ Treg population was more prone to produce Th2 cytokines, while the Tresp population was primarily responsible for the production of Th1 cytokines. In additional studies, half of the Th2 (IL-4) cytokine-producing DR Ϫ Treg were found to express Foxp3 protein (data not shown), indicating that at least a significant portion of the Th2 cytokines produced in these cultures are derived from DR Ϫ , Foxp3 ϩ natural Treg. The qualitatively different and stronger signals associated with ␣CD28 costimulation again altered the behavior of these functionally distinct Treg populations. With ␣CD28 costimulation, the Tresp exhibited greater levels of proliferation and cytokine production (Fig. 2C) Treg also induced an increase in Th2 cytokine secretion. Because the Tresp-only cultures continued to increase their proliferation during this time, the decrease in proliferation in the 4-and 5-day cocultures was not due to culture exhaustion.
Differential expression of IL-10 and kinetics of superinduction of Foxp3 by stimulated DR ϩ and DR Ϫ Treg subsets
Due to the distinct kinetics of inhibition by DR ϩ and DR Ϫ Treg, we examined whether these regulatory populations alter their expression of Foxp3 mRNA over time in relation to their temporal changes in suppressive activity. Because ␣CD3/␣CD2 costimulation produces a striking difference in the kinetics of suppression by these two Treg subsets, cultures were set up in which Tresp alone, DR ϩ Treg alone, or DR Ϫ Treg alone were stimulated with ␣CD3/ ␣CD2 in the presence or absence of IL-2. The cells were recollected after 3 and 5 days of stimulation with and without IL-2. Real-time PCR analysis of the mRNA isolated from these subsets indicated that, after 3 days of stimulation in the absence of IL-2, the levels of Foxp3 mRNA did not change appreciably from direct ex vivo levels (Fig. 3A) . In contrast, when stimulated in the presence of IL-2, the DR ϩ Treg exhibit an additional 8-fold superinduction of Foxp3 message on day 3 when they also exhibit strong suppression. Yet, after 5 days of stimulation, the level of DR ϩ Treg Foxp3 expression is greatly decreased. In comparison, in response to the same IL-2 supplemented stimulation, the DR Ϫ Treg do not exhibit their maximal induction of Foxp3 mRNA until day 5, which correlates with their kinetics of maximal suppressive activity. Low-level Foxp3 mRNA also was induced in similarly stimulated Tresp, although the levels were significantly lower than those found in the Treg populations. Thus, these data indicate that, while Foxp3 mRNA can be expressed in activated, human nonregulatory CD4 T cells, as reported by others (35) , it is expressed at Ͼ20-fold higher levels by activated Treg populations in an IL-2-dependent fashion, and its induction correlates with early suppression in DR ϩ Treg cocultures and delayed regulation in DR Ϫ Treg cocultures. The similar analysis of RNA isolated from DR ϩ and DR Ϫ Treg that had been reisolated from suppressive ␣CD3/␣CD2 stimulated cocultures (no IL-2) showed a highly similar further induction of Treg Foxp3 message (data not shown).
The DR ϩ Treg, DR Ϫ Treg, and DR Ϫ Tres cells also were assessed for their ability to express IL-10, an inhibitory cytokine that has been shown to be involved in the function of CD4 ϩ CD25 ϩ and Tr1 regulatory cells in both mouse and man (27) . Although the cells did not express detectable amounts of IL-10 mRNA when analyzed directly ex vivo (day 0), IL-10 message could be detected 3 and 5 days after in vitro activation. The values of IL-10 amplification were again normalized to the levels of ␤ 2 m by real-time PCR (Fig. 3B) . As indicated, ␣CD3/␣CD2-stimulated DR ϩ Treg did not express IL-10 mRNA regardless of the presence or absence of exogenous IL-2, while both the DR Ϫ Treg and Tresp populations produced message for IL-10 within 3 days of stimulation.
IL-10 is a component of the suppressive repertoire of DR Ϫ Treg
Studies were then performed to assess the contact dependence and potential involvement of IL-10 in DR ϩ or DR Ϫ Treg suppression because the classical CD4 ϩ CD25 ϩ Treg are known to suppress via a cell contact-mediated mechanism, while the ability of the DR Ϫ Treg to produce IL-10 suggests that they could suppress via its secretion. Contact dependence was assessed by Transwell assays in which the Tresp were cultured in the lower chamber and the DR ϩ or DR Ϫ Treg were stimulated either separately in the upper chamber or together with the Tresp in the lower chamber in the presence (open) or absence (filled) of neutralizing ␣IL-10 mAb (Fig. 4) . Both upper and lower chambers received ␣CD2/␣CD3 stimulation, and proliferation in the lower chambers was assessed at day 5 when both the DR ϩ and DR Ϫ Treg cocultures show inhibition. The addition of ␣IL-10 had no effect on the proliferation of the Tresp alone. The separate stimulation of DR ϩ Treg in the upper chamber also had no affect on the proliferation of Tresp in the lower compartment. However, if the DR ϩ Treg were stimulated in the lower chamber in contact with the Tresp, proliferation was suppressed by Ͼ50%. Thus, these data indicated that the DR ϩ Treg require cell contact to exert suppression.
In contrast with the suppression by the DR ϩ Treg subset, the Transwell analysis of DR Ϫ Treg function indicated that these cells can mediate suppression via the secretion of IL-10 as well as via a cell contact-dependent mechanism. The DR Ϫ Treg were able to directly inhibit Tresp proliferation via the secretion of IL-10, because the Tresp proliferation decreased by 40% when the DR Ϫ Treg were stimulated in the upper chamber in the absence of ␣IL-10. However, when IL-10 was neutralized in replicate wells, the ability of the DR Ϫ Treg to suppress across the membrane was abrogated as it resulted in full Tresp proliferation. Thus, the DR Ϫ Treg subset can directly suppress the proliferation of Tresp via the secretion of IL-10. However, these data also show that DR Ϫ Treg can induce a more vigorous suppression via an IL-10-independent, cell contact-dependent mechanism, because a significantly greater suppression occurred in the cocultures where cell contact was allowed that was only marginally reduced by neutralizing IL-10 (Fig. 4) . Thus, suppression by DR ϩ Treg absolutely requires cell contact, while DR Ϫ Treg can suppress by either the secretion of IL-10 or via a cell contact-dependent mechanism.
T cell clones from DR ϩ and DR Ϫ Treg populations exhibit an increased propensity to constitutively express CD25 and HLA-DR
A fundamental question in the biology of human T cells is whether the expression of MHC-DR on directly ex vivo-isolated CD4 T cells is a stable phenotype of a subset of T cells that would maintain DR expression with longer-term culture or whether DR is simply acquired with activation. It has been reported previously that suppressive human CD4 ϩ CD25 ϩ Treg clones, generated by PHA/IL-2 stimulation, maintain high levels of CD25 on their surface 2 wk after in vitro stimulation, while CD25 expression is at baseline levels on non-Treg 2 wk after activation (27) . We previously generated clones of CD4 ϩ CD25 high cells under the same stimulatory conditions and observed similar findings (18) . In this study, T cell clones were generated by single cell cloning of CD4 into single wells and expanded as described. Three weeks after a single restimulation, regardless of their level of expansion, every clone was tested for its ability to suppress the proliferation of freshly isolated autologous Tresp and was thus classified as suppressive (filled) or nonsuppressive (open) (Fig. 5) . The two Treg populations exhibited markedly different cloning capacity as the DR ϩ Treg consistently grew less well, while over two-thirds of wells seeded with DR Ϫ Treg produced clones (Table I) . When tested for functional activity, the DR ϩ and DR Ϫ Treg subsets gave rise to the highest frequencies of suppressive clones. However, in contrast with the assay of bulk ex vivo DR Ϫ Treg, the suppressive clones derived from the DR Ϫ Treg population no longer induced IL-4 or IL-10 during culture (Fig. 5B ). Furthermore, when tested for surface expression of CD25 and DR 24 days after their last activation (Fig. 5D) , 40% of the suppressive clones derived from the DR Ϫ Treg population now expressed DR (13 of 32), while 44% of those from the DR ϩ Treg population expressed DR. In striking contrast, no clones derived from the DR ϩ CD25 Ϫ/low population and only 2% (1 of 50) of the DR Ϫ CD25 Ϫ -derived clones expressed DR. Thus, the initial ex vivo expression of high CD25 levels strongly correlated with subsequent clonal expression of DR, while the initial expression of DR on CD25 Ϫ/low cells did not predict long-term expression of DR. In addition, although both the DR ϩ and DR Ϫ CD25 high populations gave rise to suppressive and nonsuppressive clones that did not express DR, virtually all the DR expressing clones were suppressive (4 of 5 and 13 of 14, respectively). Thus, DR expression is associated with a strong suppressive activity by ex vivo CD4 ϩ CD25 high cells and by roughly half of the suppressive clones generated from either the DR ϩ or DR Ϫ Treg populations. These clone data indicate that the functional distinctions between the DR ϩ Treg and DR Ϫ Treg populations are observed only ex vivo, as further differentiated DR ϩ Treg or DR Ϫ Treg no longer function in a distinct fashion. Thus, these data lead us to hypothesize that DR may identify a mature and highly active regulatory CD4 ϩ CD25 high cell and not a separate T cell lineage. In an attempt to elucidate the suppressive mechanism(s) used by these clones, real time PCR analysis for Foxp3, IL-10 and TGF␤ was performed on RNA isolated from a set of representative clones from each group (Fig. 6) . Thus, although the DR ϩ and DR Ϫ Tresp ex vivo populations express little Foxp3 message as a whole, 18% of the clones derived from these populations expressed high levels of Foxp3 mRNA (Fig. 6A) after their clonal expansion, even though they were not suppressive in the in vitro assays. In contrast, Table I for cloning efficiency data). Twenty-one days after a single restimulation, each clone was examined for expression of CD25 and HLA-DR (D) and tested for suppressor function in a 3-day, ␣CD3-stimulated, dose-response coculture assay with 3 ϫ 10 3 Tresp/well measuring proliferation (A) and cytokines (B and C). Each clone was classified as suppressive (F) or responder (E) based on coculture proliferation. Long-term DR expression depended on initial ex vivo expression of CD25 high and was associated with suppression by ex vivo CD4
ϩ CD25 high cells and by long-term T cell clones. high . These data also indicate that high levels of Foxp3 are maintained in the clones derived from the CD25 high populations regardless of their functional suppressive ability. The amount of TGF␤ mRNA (Fig. 6B) produced by each clone did not correlate with either its suppressive ability or its original cloning group. In contrast, the results of the IL-10 expression analysis (Fig.  6C ) not only corroborate the lack of IL-10 production in cocultures with Treg clones, but also suggest that at least a subset of the suppressive clones derived from the DR Ϫ Tresp population may be Tr1-like in their mechanism of action, as they express IL-10 but lack Foxp3.
Discussion
It has been known for decades that circulating human CD4 cells can express functional MHC-II molecules that induce T cell nonresponsiveness with Ag presentation. Based on these observations and our more recent data demonstrating the expression of DR on a subpopulation CD4 
CD25
Ϫ/low cells) did not predict the later, long-term constitutive expression of DR on differentiated T cell clones. Furthermore, DR ϩ T cell clones generated from the DR Ϫ Treg subset functioned similarly to the ex vivo DR ϩ Treg population, as they suppressed in the absence of the induction of IL-4 or IL-10.
Almost all of the clones that exhibited constitutive DR expression had been derived from the CD25 high Treg populations. Although the DR ϩ Treg exhibit much lower cloning efficiency, approximately half of the suppressive DR ϩ Treg-derived clones and a similar percentage of the suppressive DR Ϫ Treg-derived clones expressed HLA-DR constitutively. In contrast, only 1 of 50 clones generated from the DR Ϫ Tresp population constitutively expressed DR or exhibited in vitro suppressive activity. The clones derived from the DR ϩ Tresp population did not subsequently exhibit constitutive DR expression, suggesting that their original expression of DR may have been related to their state of activation. Thus, even though ex vivo DR expression does define differences in the ex vivo function of Treg populations, the clonal analysis indicates that, while all suppressive clones do not necessarily express DR, all DR expressing clones are suppressive. The real-time PCR analysis of representative clones from these T cell subsets revealed that suppression by the clones derived from the DR ϩ and DR Ϫ Treg subsets did not correlate with production of IL-10 or TGF␤, suggesting that these inhibitory cytokines are not involved in their suppressive mechanism. In contrast, because two of the suppressive clones generated from the Tresp contained high levels of IL-10 and lacked Foxp3 mRNA, these clones may represent Tr1 regulatory cells. More surprising was the observation that 90% of the clones derived from DR ϩ Treg population maintained high expression of Foxp3 regardless of their in vitro suppressive activity or their expression of DR. These data indicate that nonsuppressive DR ϩ Treg-derived clones did not originate from activated effector cells contaminating the original Treg population. These data also confirm that within the CD25 high population, DR expression identifies a population of distinct contact-dependent suppressor cells that maintain high levels of Foxp3.
We also observed a strong correlation between the kinetics of induced Foxp3 transcription and contact-dependent suppression in 
high populations maintain high levels of Foxp3 mRNA regardless of their in vitro suppressive ability. RNA was isolated from those T cell clones that were generated and assayed in Fig. 5 , and that had expanded to sufficient numbers. These 6 -10 clones per subset contained both suppressive (F) and nonsuppressive (E). Real-time PCR was used to comparatively assess the relative expression of Foxp3 (A), TGF␤ (B), and IL-10 (C) in these clones, compared with endogenous ␤ 2 m. The levels of Foxp3 mRNA in the clones derived from the CD25 high populations were significantly higher than that expressed by the clones derived from the CD25 Ϫ populations (p Ͻ 0.0001, Mann-Whitney U test), while there was no significant differences between the groups in their expression of TGF␤ or IL-10.
both DR ϩ and DR Ϫ Treg populations. Foxp3 was typically expressed at slightly higher levels ex vivo in DR ϩ than in the DR Ϫ Treg. When stimulated in the presence of exogenous IL-2, the two Treg subsets exhibited differences in the kinetics of additional Foxp3 mRNA induction. Because the levels of Foxp3 message did not change if either type of Treg was stimulated in the absence of IL-2, IL-2 may play a role in maintaining the suppressive activity of these cells as has been suggested previously (38) . Therefore, in the typical ␣CD3/␣CD2-stimulated coculture, low amounts of IL-2 may be provided by the activated Tresp that is used by the CD25 high DR ϩ and DR Ϫ Treg to induce distinct kinetics of Foxp3 superinduction and suppressive function.
Although a fundamental role for Foxp3 in regulation was demonstrated by studies showing that transfection of the Foxp3 gene into mouse or human CD4 ϩ CD25 Ϫ T cells resulted in acquired regulatory phenotype and function (30, 31, 39) , it is not present in all types of Treg. The ability of DR Ϫ Treg to produce IL-10 and suppress the proliferation of other T cells is reminiscent of Tr1 regulatory cells, while the strong induction of Th2 cytokines, the contact-dependent component of DR Ϫ Treg suppression (see Fig.  4 ), and the elevated Foxp3 expression by the DR Ϫ Treg distinguish them from Tr1 cells (35) . Rather, the analysis of clonal gene expression may suggest that Tr1 regulatory cells originate from within the DR Ϫ Tresp population. Regardless, because the cell contact-dependent suppression by freshly isolated DR ϩ and DR
Ϫ
Treg subsets is not abrogated by the neutralization of IL-10 or TGF␤ (data not shown), they are truly distinct from Tr1 regulatory cells. IL-10 has been shown to be important for CD4 ϩ CD25 ϩ Treg function in a number of in vivo disease models in mice, although the corresponding in vitro assays often showed no role for IL-10. Specifically, an in vivo but, not in vitro, dependence on IL-10 has been shown in studies addressing Treg activity in autoimmune colitis (12, 40, 41) , expansion of the memory CD4 T cells in lymphopenic hosts (20) , and the development of experimental autoimmune encephalomyelitis (42) , while there are other in vivo autoimmune models that show no IL-10 involvement in Treg activity (11, 40, 43, 44) . The in vivo and in vitro discrepancies could be due to the study of heterogeneous Treg populations and the fact that Treg likely act individually in vivo but are assayed as total populations when tested in vitro. We have found that the individual types of Treg (DR ϩ and DR Ϫ ) alter each other's function when assayed together. These data and previous studies indicate that the individual characteristics of the DR ϩ and DR Ϫ Treg populations are lost when they are assayed together for in vitro function (data not shown and Refs. 15, 17, 18, 45) . Thus, the additional interactions that occur in the study of mixed Treg populations may obscure the mechanisms of action of specific types of Treg cells, indicating that, in future human studies, subfractionation of these Treg populations will be required.
In summary, we demonstrate that MHC-DR expression defines two functionally distinct CD4 ϩ CD25 ϩ Treg populations in humans. The DR ϩ Treg population exhibits early contact-dependent suppression, while the DR Ϫ Treg population initially skews the immune response toward the production of Th2 cytokines before initiating a late, Foxp3-associated, contact-dependent suppression. Single-cell cloning of CD25 high Treg reveals that DR expression is associated with suppressive function. These data indicate that MHC-II expression on CD4 ϩ CD25 high Treg identifies a mature, distinct Treg involved in contact-dependent in vitro suppression. Thus, future analysis of human Treg will require examination of these functionally distinct subsets found in the total CD4 ϩ CD25 high Treg population.
